MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/ppa.s496736

Медицинская библиотека · Patient preference and adherence · 2025

Patient Preferences for Episodic Migraine Medications: A Discrete Choice Experiment of Self-Injectable Versus Oral Treatments Targeting Calcitonin Gene-Related Peptide Pathway.

Whichello Chiara, Viktrup Lars, Varnado Oralee J, Quaife Matthew, Trapali Myrto, Tockhorn-Heidenreich Antje

СтатьяПеревод в очереди

Аннотация

PURPOSE: To understand the trade-offs that patients with episodic migraine are willing to make between attributes of self-injectable calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) and oral small-molecule calcitonin gene-related peptide receptor antagonists (gepants).

PATIENTS AND

METHODS

This was an online discrete choice experiment survey among adults with episodic migraine (≥4 and <15 migraine headache days and <15 headache days per month over 3 months) in the United States. Hypothetical treatments were characterized by five attributes: chance of ≥50% migraine reduction, impact on daily activities, onset of treatment effect, reduction in number of acute medications, and treatment administration. The attributes were selected based on insights gained from a previously conducted literature review and focus group study and aligned with the primary and secondary outcome measures in the double-blind Phase IV head-to-head clinical trial of a CGRP mAb versus gepant.

RESULTS

601 patients (mean age: 44.8 years) completed the survey. Treatment preferences differed significantly between patients. However, for all patients, the most important driver of treatment preferences was the chance of a ≥50% reduction in monthly migraine headache days (relative attribute importance: 38.3%), followed by the impact on daily activities (23.5%), the onset of treatment effect (19.5%), the reduction in need for acute medication (15.4%), and finally the route of administration (3.4%). Patients were willing to consider a one-week delayed onset of treatment effect or one-day increased need for acute medication for a higher chance (by 2.06% and 2.65% respectively) of a ≥50% reduction in monthly migraine headache days. Patients would trade a reduction of migraine's impact on daily activities from "extreme" to "moderate" or "minimal" with a lower chance (17.09%, 12.06% respectively) of halving the number of monthly migraine headache days.

CONCLUSION

A ≥50% reduction in monthly migraine headache days was the most important treatment attribute for which participants were willing to trade against other attributes. The variation in treatment preferences between patients emphasizes the importance to align decision-making with individual patients' preferences.

Для цитирования: Whichello Chiara, Viktrup Lars, Varnado Oralee J, Quaife Matthew, Trapali Myrto, Tockhorn-Heidenreich Antje. Patient Preferences for Episodic Migraine Medications: A Discrete Choice Experiment of Self-Injectable Versus Oral Treatments Targeting Calcitonin Gene-Related Peptide Pathway.. Patient preference and adherence. 2025. DOI: 10.2147/ppa.s496736.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.